Searchable abstracts of presentations at key conferences in endocrinology

ea0062p28 | Poster Presentations | EU2019

Alemtuzumab induced thyrotoxicosis in a patient undergoing autologous haematopoietic stem cell transplant for multiple sclerosis

Esdaile Harriet , Hinton Richard , Sheridan Helena , Rogosic Srdan , Pavlu Jiri , Olavarria Eduardo , Gabriel Ian

Case History: A 37 year old female underwent an elective autologous stem cell transplant (ASCT) for multiple sclerosis (MS), with cyclophosphamide and anti-thymocyte (ATG) conditioning. She had previously received two doses of alemtuzumab, with the last dose 12 months prior to ASCT. Baseline thyroid function was normal pre atemluzumab. 3 months prior to dose 2 (18 months post first dose), subclinical hyperthryoidism was present with a raised TSH antibody (0.08 unit/ml). There ...

ea0032p359 | Diabetes | ECE2013

Reconsidering guidance for postnatal glucose screening in gestational diabetes

Jarvis Sheba , Feben Christine , Roy Stephanie , Sheridan Richard , Boret Tony , Trainor Orla , Clements Michael R

Background: National Institute for Health and Clinical Excellence (NICE) guidelines advise that GDM be diagnosed using a 2-hr 75 g oral glucose tolerance test (OGTT). However there is lack of consensus on the optimal postpartum surveillance. Current postpartum screening guidance suggests a single fasting plasma glucose (FPG) at 6-weeks with annual testing thereafter. As women with GDM are often from mixed ethnic groups and frequently have postprandial hyperglycaemia, ...

ea0094p53 | Metabolism, Obesity and Diabetes | SFEBES2023

The role of glycated haemoglobin in predicting disease severity in non-alcoholic fatty liver disease

Colosimo Santo , Miller Hamish , Koutoukidis Dimitrios , Marjot Thomas , Tan Garry , Harman David , Aithal Guruprasad , Manousou Pinelopi , Forlano Roberta , Parker Richard , Sheridan David , Newsome Philip , Alazawi William , Cobbold Jeremy , Tomlinson Jeremy

Introduction: The relationship between non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes is well-established. However, the precise impact of glucose control on the severity and progression of NAFLD remains largely unexplored. Currently, none of the non-invasive scoring systems used to assess NAFLD severity incorporate glucose control markers, such as glycated hemoglobin (HbA1c).Methods: Data were collected fr...